AC Immune logo
AC Immune
ACIU | NASDAQ
Chart Builder DCF Calculator
$2.09
-$0.04 (-1.88%)
At close: Nov 16, 2026, 4:00 PM ET
$2.09
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

AC Immune Company Profile

Company profile explained

Company Profile

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.

Key Executives

Name Position
Martin Zugel Interim CEO & Chairman of the Board
Christopher Roberts Chief Financial Officer & Vice President of Finance
Piergiorgio Donati Chief Operating Officer
Bojana Portmann SVP of Intellectual Property,Intellectual Property & Business Development
Francesca Capotosti Senior Vice President of Research
Gary Anthony Waanders Senior Vice President of Investor Relations & Corporate Communications
Günther Staffler Executive Vice President of Development
Julien Rongere Senior Vice President of Regulatory Affairs & Quality Assurance
Mark Danton Executive Vice President of Information Systems & Artificial Intelligence
Matthias Maurer Senior Vice President & General Counsel
Oliver Sol Vice President & Head of Clinical Development

Latest SEC Filings

Date Type Title
Oct 09, 2026 3/A [Amend] Filing
Oct 09, 2026 3 Filing
Oct 02, 2026 6-K Filing
Sep 23, 2026 6-K Filing
Sep 03, 2026 6-K Filing
Aug 20, 2026 6-K Filing
Aug 11, 2026 6-K Filing
Aug 05, 2026 6-K Filing
Jun 30, 2026 6-K Filing
Jun 15, 2026 4 Filing
View All SEC Filings ➞
AC Immune
AC Immune logo
Country Switzerland
IPO Date Sep 23, 2016
Industry Biotechnology
Sector Healthcare
Employees 106
CEO Martin Zügel

Contact Details

Building B Lausanne, VD 1015 Switzerland

Stock Details

Ticker Symbol ACIU
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001651625
CUSIP Number H00263105
ISIN Number CH0329023102
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.